Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13183MR)

This product GTTS-WQ13183MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13183MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ832MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ2181MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ15031MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ1286MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ11240MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ9589MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ12638MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ10512MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW